MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
3-year psoriasis drug trial shows lasting skin clearance for many
Disease control CompletedThis study followed over 1,300 adults with moderate to severe plaque psoriasis for up to 3 years to see how safe and effective the medication bimekizumab is over the long term. Participants received regular injections of the drug and were monitored for side effects and skin impro…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
New psoriasis drug goes Head-to-Head with established treatment
Disease control CompletedThis study tested whether a new injectable drug called bimekizumab works better than an existing drug called secukinumab for adults with moderate-to-severe plaque psoriasis. 743 participants received one of the two drugs for 48 weeks, with researchers measuring how much their ski…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
New psoriasis drug goes Head-to-Head with established treatment
Disease control CompletedThis study tested a new drug called Bmab 1200 against an already approved drug, Stelara, to see if it works as well for controlling moderate to severe plaque psoriasis. About 384 adults with this skin condition received one of the two drugs for a year, and researchers measured ho…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug shows promise for Near-Total skin clearance in psoriasis
Disease control CompletedThis study tested an investigational drug called bimekizumab in adults with moderate to severe plaque psoriasis. It was a large, late-stage trial comparing the drug to a placebo to see how well it cleared skin and reduced symptoms like itch and pain. The main goal was to see if p…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New injection shows promise for clearing severe psoriasis
Disease control CompletedThis study tested whether a new injectable medication called JS005 can safely and effectively treat moderate to severe plaque psoriasis. It involved 747 adults who received either JS005 at one of two doses or a placebo injection. The main goal was to see how many patients achieve…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for kids with severe skin condition
Disease control CompletedThis study observed 42 children and teenagers in China with moderate to severe plaque psoriasis who were prescribed the medication Cosentyx. It aimed to collect real-world safety information and see how well the drug worked to clear or nearly clear their skin over one year. The s…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New drug shows promise for clearing severe skin plaques
Disease control CompletedThis study tested an investigational drug called bimekizumab for adults with moderate to severe plaque psoriasis. It compared bimekizumab against a placebo and an existing treatment to see how well it cleared skin plaques and reduced symptoms like itch and pain. The main goal was…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
New psoriasis drug shows promise for dramatic skin clearance
Disease control CompletedThis study tested whether an injectable drug called bimekizumab is better than a placebo at clearing skin in adults with moderate to severe plaque psoriasis. It involved 133 Chinese participants who received injections for 16 weeks. Researchers measured how much the psoriasis imp…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 02, 2026 15:23 UTC